AIM Vaccine Co., Ltd. Class H stock analysis
Want to see HK:6660 full AI Analyst Report?
AIM Vaccine Co., Ltd. Class H (6660) Stock Price & Analysis
6660 Stock Chart & Stats
- Day’s Range
- HKD 1.50 - HKD 1.50
- 52-Week Range
- HKD 1.20 - HKD 3.78
- Previous Close
- HKD 1.50
- Volume
- N/A
- Average Volume (3M)
- 117.81K
- Market Cap
- HKD 1.83B
- Enterprise Value
- HKD 4.06B
- Total Cash (Recent Filing)
- HKD 193.15M
- Total Debt (Recent Filing)
- HKD 1.77B
- Price to Earnings (P/E)
- ―
- Beta
- 1.22
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Integrated Vaccine Business
The company spans vaccine research, development, manufacturing, and commercialization, giving it control across the product lifecycle. This integrated model can support better coordination between development and distribution, while an established focus on the Chinese market provides a defined platform for future product adoption.
Strong Gross Margins
Gross margins of roughly 62%–74% indicate that the underlying vaccine products retain meaningful economic value before operating expenses. If maintained, this margin structure can provide a foundation for recovery as revenue scales, although the company still needs to address the high costs that currently prevent profitability.
Positive Operating Cash Flow
Positive operating cash flow in the latest two periods suggests the core business is generating cash from operations despite reported losses. This is a constructive foundation for financial durability because it may help fund routine activity internally, even though investment spending continues to keep free cash flow negative.
Bears Say
Revenue Decline
The return to revenue contraction after only modest prior growth points to weak near-term commercial momentum. Persistent top-line pressure can reduce operating leverage, limit the company’s ability to absorb fixed costs, and make it harder for strong gross margins to translate into sustainable earnings over the next several quarters.
Persistent Losses
Large net losses, negative operating profitability, and a -23.84% return on equity show that the business is not currently converting its platform into shareholder returns. Continued losses could consume capital, constrain reinvestment, and increase the risk of further value dilution if profitability does not recover.
Negative Free Cash Flow
Ongoing negative free cash flow means investment spending continues to exceed internally generated cash, despite positive operating cash flow. If this pattern persists, the company may need additional funding to support development and operations, reducing financial flexibility and potentially increasing reliance on external capital.
AIM Vaccine Co., Ltd. Class H News
AIM Vaccine Seeks Shareholder Nod for Private Domestic Share Issue and Dual Mainland Listings
AIM Vaccine Co., Ltd. Class H ( ($HK:6660) ) has shared an announcement. AIM Vaccine Co., Ltd., a Hong Kong-listed biopharmaceutical company focused on vaccine development and commercialization, plans to
6660 FAQ
What was AIM Vaccine Co., Ltd. Class H’s price range in the past 12 months?
What is AIM Vaccine Co., Ltd. Class H’s market cap?
When is AIM Vaccine Co., Ltd. Class H’s upcoming earnings report date?
How were AIM Vaccine Co., Ltd. Class H’s earnings last quarter?
Is AIM Vaccine Co., Ltd. Class H overvalued?
Does AIM Vaccine Co., Ltd. Class H pay dividends?
What is AIM Vaccine Co., Ltd. Class H’s EPS estimate?
How many shares outstanding does AIM Vaccine Co., Ltd. Class H have?
What happened to AIM Vaccine Co., Ltd. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AIM Vaccine Co., Ltd. Class H?
What is the TipRanks Smart Score and how is it calculated?
AIM Vaccine Co., Ltd. Class H Stock Smart Score
Company Description
AIM Vaccine Co., Ltd. Class H
Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yan Zhou
- Employees
- 1,466
- Website
- www.aimbio.com
- Address
- CN
AIM Vaccine Co., Ltd. Class H (6660) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |








